Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Pereira, Flávia Ozorio ^a   Frode, Tânia Silvia ^b   Medeiros, Yara Santos ^a,b  

^a Governador Celso Ramos Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 2 RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEMOGLOBINOPATHY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATORY DISEASE; INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX; AGED; BLOOD; CLINICAL CHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; RISK;

ADULT; AGED; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; NITRIC OXIDE; RECEPTORS, INTERLEUKIN-2; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645225586     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/39062     Document Type: Article

References (32)

1. United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk ot complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA: The Journal of the American Medical Association. 2001;285(19):2486-2497.
3. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329(14):977-986.
4. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.
5. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Analytical Biochemistry. 1982;126(1):131-138.
6. Di Rosa M, Ialenti A, Ianaro A, Sautebin L. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1996;54 (4):229-238.
7. Ellis G, Adatia I, Yazdanpanah M, Makela SK. Nitrite and nitrate analyses: a clinical biochemistry perspective. Clinical Biochemistry. 1998;31(4):195-220.
8. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79-S83.
9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-369.
10. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. The American Journal of Medicine. 2002;112(4):275-280.
11. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149-2153.
12. Matata BM, Galinanes M. Effect of diabetes on nitric oxide metabolism during cardiac surgery. Diabetes. 2001;50(11):2603-2610.
13. Ozden S, Tatlipinar S, Bicer N, et al. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Canadian Journal of Ophthalmology. 2003;38(5):393-396.
14. Chiarelli F, Cipollone F, Romano F, et al. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes. 2000;49(7):1258-1263.
15. Aydin A, Orhan H, Sayal A, Ozata M, Sahin G, Isimer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clinical Biochemistry. 2001;34(1):65-70.
16. Piatti PM, Monti LD, Zavaroni I, et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2000;85(7):2416-2420.
17. Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16(2):163-170.
18. Castillo FM, Romero TA, Estévez J, et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clinical and Diagnostic Laboratory Immunology. 2002;9(6):1372-1375.
19. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-240.
20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine. 1998;339(4):229-234.
21. Nakae H, Endo S, Kikuchi M, et al. Nitrite/nitrate (NOx) levels and hemodynamics during septic shock. Surgery Today. 2000;30(8):683-688.
22. Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. Journal of the American College of Cardiology. 2004;43(5):771-777.
23. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. 2001;22(1):36-52.
24. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine. 2004;350(14):1387-1397.
25. Wolford JK, Gruber JD, Ossowski VM, et al. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Molecular Genetics and Metabolism. 2003;78(2):136-144.
26. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27(4):889-894.
27. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine. 2002;347(20):1557-1565.
28. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005;352(16):1685-1695.
29. Norris CM, Ghali WA, Galbraith PD, Graham MM, Jensen LA, Knudtson ML. Women with coronary artery disease report worse health-related quality of life outcomes compared to men. Health and Quality of Life Outcomes. 2004;2(1):21.
30. King KM, Ghali WA, Faris PD, et al. Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time. JAMA: The Journal of the American Medical Association. 2004;291(10):1220-1225.
31. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews. 1997;5(4):294-315.
32. Smitherman TC, Reis SE. Heart disease in women with diabetes. Diabetes Spectrum. 1997;10(3):207-215.